

LIST OF REFERENCES CITED BY APPLICANT <i>(Use several sheets if necessary)</i>	ATTY. DOCKET NO.	APPLICATION NO.
	8002-082-999	10/738, 423 To Be Assigned (Divisional of U.S. Application Serial No.: 09/645,415)
	APPLICANT	King
FILING DATE	GROUP	
Herewith	1614	

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
QJL	A01	09/645,418		Bermudes et al. <i>[Signature]</i>			8/24/00
	A02	2001/0029043	10/11/01	Haefliger et al.			
	A03	2001/0006642	7/5/01	Steidler et al.			
	A04	6,537,558	3/25/03	Kaniga			
	A05	6,410,012	6/25/02	Sizemore			
	A06	6,251,406	6/26/01	Haefliger et al.			
	A07	6,190,657	2/20/01	Pawelek			
	A08	6,150,170	11/21/00	Powell et al.			
	A09	6,080,849	9/10/97	Bermudes et al.			
	A10	5,997,881	12/7/99	Powell et al.			
	A11	5,877,159	3/2/99	Powell et al.			
	A12	5,824,538	10/20/98	Branstrom			
	A13	5,705,151	1/6/98	Dow et al.			
	A14	5,344,762	9/6/94	Karapetian			
	A15	5,021,234	6/4/91	Ehrenfeld			
QJL	A16	4,436,727	3/13/84	Ribi			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
QJL	B01	WO 9106317	5/16/91	PCT			
QJL	B02	WO 9211361	7/9/92	PCT			
QJL	B03	WO 9502048	1/19/95	PCT			
QJL	B04	WO 9611277	4/18/96	PCT			
QJL	B05	WO 9640238	12/19/96	PCT			

/Q. Janice Li/ (06/27/2006)

QJL	B06	WO 9718837	5/29/97	PCT			
	B07	WO 9719688	6/5/97	PCT			
	B08	WO 9725061	7/17/97	PCT			
	B09	WO 9833923	8/16/98	PCT			
	B10	WO 9634631	11/7/96	PCT			
	B11	WO 9718225	5/22/97	PCT			
	B12	WO 9853854	12/3/98	PCT			
	B13	WO 9913003	3/18/99	PCT			
	B14	WO 9952563	10/21/99	PCT			
	B15	WO 00/09733	2/24/00	PCT			
QJL	B16	WO 02/20809	3/14/02	PCT			

**OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)**

QJL	C01	Adler, 1973, "A Method for Measuring Chemotaxis and Use of the Method to Determine Optimum Conditions for Chemotaxis by <i>Escherichia col.</i> , i" J. Gen. Microbiol. 74:77-91
	C02	Alizadeh et al., 1994, "Apoptosis as a Mechanism of Cytolysis of Tumor Cells by a Pathogenic Free-Living Amoeba," Infect. Immun. 62:1298-1303
	C03	Anderson et al., 1996, "Development of attenuated <i>Salmonella</i> strains that express heterologous antigens," Methods in Molecular Medicine: Vaccine protocols, ed. Robinson A, Farrar G, Wiblin C., Humana Press New Jersey, pp.47-62
	C04	Anderson WF, 2001, "Recombinant DNA Advisory Committee Meeting on Issues of Concern to IBCs," Human Gene Therapy 12(12):1594-1596
	C05	Bagshawe, 1995, "Antibody-Directed Enzyme Prodrug Therapy: A Review," Drug Dev. Res. 34:220-230
	C06	Barry et al., 1995, "Protection Against Mycoplasma Infection Using Expression-Library Immunization," Nature 377:632-635
	C07	Barth and Morton, 1995, "The Role of Adjuvant Therapy in Melanoma Management," Cancer 75 (Suppl.):726-734
	C08	Berggren, 1995, "Recombinant Salmonella as an Oral HIV Vaccine," NIH Project Number 5 K08 AI01248-02
	C09	Bermudes et al., 2000, "Tumor targeted Salmonella. Strain development and expression of the HSV TK effector gene," Gene Therapy, Methods and Protocols, Vol. 35, 419-436
	C10	Bermudes et al., 2000, 'Tumor-targeted Salmonella.Highly selective delivery vectors,' Advances in Exp. Med. And Bio. 465:57-63
	C11	Boehm et al., 1997, "Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance," Nature 390(6658):404-407
	C12	Bone, 1993, "Gram-Negative Sepsis: A Dilemma of Modern Medicine," Clin. Microbiol. Rev. 6:57-68
	C13	Bonnekoh et al., 1995, "Inhibition of Melanoma Growth by Adenoviral-Mediated HSV Thymidine Kinase Gene Transfer <i>in vivo</i> ," J. Invest. Derm. 104:313-317
	C14	Carey et al., "Clostridial Oncolysis in Man," Eur. J. Cancer 3:37-46
	C15	Carrier et al., 1992, "Expression of Human IL-1 $\beta$ in <i>Salmonella typhimurium</i> ; a Model System for the Delivery of Recombinant Therapeutic Proteins <i>in vivo</i> ," J. Immunol. 148:1176-1181
QJL	C16	Carswell et al., 1975, "An Endotoxin-Induced Serum Factor that Causes Necrosis of

QJL		Tumors," Proc. Natl. Acad. Sci. USA 72:3666-3670
QJL	C17	Chabalgoity et al., 1996, "A <i>Salmonella typhimurium htrA</i> Live Vaccine Expressing Multiple Copies of a Peptide Comprising Amino Acids 8-23 of Herpes Simplex Virus Glycoprotein D as a Genetic Fusion to Tetanus Toxin Fragment C Protects Mice from Herpes Simplex Virus Infection," Mol. Microbiol. 19:791-801
	C18	Chatfield et al., 1992, "Use of the <i>nirB</i> promoter to direct the stable expression of heterologous antigens in <i>Salmonella</i> oral vaccine strains: development of a single-dose oral tetanus vaccine," Biotechnology (NY) 10(8):888-92
	C19	Chatfield et al., 1992, "Construction of a genetically defined <i>Salmonella typhi</i> Ty2 <i>aroA</i> , <i>aroC</i> mutant for the engineering of a candidate oral typhoid-tetanus vaccine," Vaccine 10(1):53-60
	C20	Chen et al., 1999, "Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice," Cancer Res. 59(14):Abstract
	C21	Christ et al., 1995, "E5531, a Pure Endotoxin Antagonist of High Potency," Science 268:80-83
	C22	Clairmont et al., 2000, "Biodistribution and genetic stability of the novel antitumor agent VNP 20009, a genetically modified strain of <i>Salmonella typhimurium</i> ," J. Infect. Diseases 181:1996-2002
	C23	Clements, 1995, "Attenuated <i>Salmonella</i> as Vaccine Vectors," NIH Project Number 5 R01 AI 28835-06
	C24	Clementz et al., 1997, "Function of the <i>Escherichia coli msbB</i> Gene, a Multicopy Suppressor of <i>htrB</i> Knockouts, in the Acylation of Lipid A," J. Biol. Chem. 272(16):10353-10360
	C25	Cunningham et al., 1992, "Actin-Binding Protein Requirement for Cortical Stability and Efficient Locomotion," Science 255:325-327
	C26	Curtiss et al., 1989, "Selective delivery of antigens by recombinant bacteria," Curr Top Microbiol Immunol. 146:35-49
	C27	Curtiss, 1994, "Avirulent <i>Salmonella</i> Host-Vector Vaccine Systems," NIH Project Number 1 R41 AI36585-01
	C28	Curtiss, 1995, "Biological Containment of Live Bacterial Vaccines," NIH Project Number 1 R41 AI38599-01
	C29	Darji et al., 1997, "Oral Somatic Transgene Vaccine Using Attenuated <i>S. typhimurium</i> ," Cell 91:765-775
	C30	Eisenstadt, 1987, "Analysis of Mutagenesis," from <i>Escherichia coli and Salmonella typhimurium, Cellular and Molecular Biology</i> , Neidhardt et al. (ed.), pp. 1016-1033
	C31	Eisenstein et al., 1995, "Immunotherapy of a Plasmacytoma with Attenuated <i>Salmonella</i> ," Med. Oncol. 12:103-108
	C32	Engel et al., 1992, "Murein-metabolizing enzymes from <i>Escherichia coli</i> : existence of a second lytic transglycosylase," J. Bacteriol. 174:6394-6403
	C33	Engelbart and Gericke, 1963, "Oncolysis by Clostridia. V. Transplanted Tumors of the Hamster," Cancer Res. 24:239-243
	C34	Falkow, 1991, "Bacterial Entry into Eukaryotic Cells," Cell 65:1099-1102
	C35	Fields et al., 1989, "A <i>Salmonella</i> locus that controls resistance to microbiocidal proteins from phagocytic cells," Science 243:1059-1062
QJL	C36	Fields et al., 1986, "Mutants of <i>Salmonella typhimurium</i> that cannot survive within the macrophage are avirulent," Proc. Natl Acad Sci USA, 83:5189-5193

QJL	C37	Fox et al., 1996, "Anaerobic Bacteria as a Delivery System for Cancer Gene Therapy: in vitro Activation of 5-Fluorocytosine by Genetically Engineered Clostridia," Gene Therapy 3:173-178
	C38	Friberg, 1993, "BCG in the Treatment of Superficial Cancer of the Bladder: A Review," Med. Oncol. Tumor Pharmacother. 10:31-36
	C39	Galan et al., 1990, "Cloning and characterization of the <i>asd</i> gene of <i>Salmonella typhimurium</i> : use in stable maintenance of recombinant plasmids in <i>Salmonella</i> vaccine strains," Gene 94:29-35
	C40	Galan, 1995, "Novel <i>Salmonella</i> Antigen Delivery Vectors," NIH Project Number 5 R01 AI36520-02
	C41	Gericke and Engelbart, 1963, "Oncolysis by Clostridia. II. Experiments on a Tumor Spectrum with a Variety of Clostridia in Combination with Heavy Metal," Cancer Res. 24:217-221
	C42	Gill et al., 1996, "A malignant pleural effusion infected with <i>Salmonella enteritidis</i> ," Thorax 51(1):104-5
	C43	Gonzalez et al., 1994, " <i>Salmonella typhi</i> vaccine strain CVD 908 expressing the circumsporozoite protein of <i>Plasmodium falciparum</i> : strain construction and safety and immunogenicity in humans," J. Infect. Dis. 169(4):927-31
	C44	Gulig, 1994, " <i>Salmonella typhimurium</i> Virulence Plasmid," NIH Project Number 5 R29 AI28421-05
	C45	Hakkaart et al., 1981, "Protein H encoded by plasmid Clo DF13 involved in lysis of the bacterial host. II. Functions and regulation of synthesis of the gene H product," Mol. Gen. Genet. 183(2):326-332
	C46	Hall et al., 1994, "Induced Regression of Bovine Papillomas by Intralesional Immunotherapy," Therapeutic Immunol. 1:319-324
	C47	Han et al., 1967, "Salmonellosis in Disseminated Malignant Diseases," New Eng. J. Med. 276:1045-1052
	C48	Hohmann et al., 1996, "phoP/phoQ-deleted <i>Salmonella typhi</i> (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers," J. Infect. Dis. 173(6):1408-14
	C49	Hohmann et al., 1996, "Evaluation of a phoP/phoQ-deleted, aroA-deleted live oral <i>Salmonella typhi</i> vaccine strain in human volunteers," Vaccine 14:19-24
	C50	Hoiseth and Stocker, 1981, "Aromatic dependent <i>Salmonella typhimurium</i> are non virulent and effective as live vaccines," Nature 291:238-239
	C51	Jain, 1994, "Barriers to Drug Delivery in Solid Tumors," Sci. American 271:58-65
	C52	Jones et al., 1992, "Invasion by <i>Salmonella typhimurium</i> is Affected by the Direction of Flagellar Rotation," Infect. Immun. 60:2475-2480
	C53	Karow and Georgopoulos, 1992, "Isolation and Characterization of the <i>Escherichia coli</i> <i>msbB</i> Gene, a Multicopy Suppressor of Null Mutations in the High-Temperature Requirement Gene <i>htrB</i> ," J. Bacteriol. 174:702-710
	C54	Kelley et al., 1993, "The <i>firA</i> gene of <i>E. coli</i> encodes UDP-3-O-(R-3-hydroxymyristoyl)-glucosamine-acetyltransferase," J. Biol. Chem. 268:19866-19874
	C55	Khan et al., 1998, "A lethal role for lipid A in <i>Salmonella</i> Infections," Mol. Microbiol. 29(2):571-579
QJL	C56	King et al., 1998, "Tumor targeted <i>Salmonella</i> expressing cytosine deaminase converted 5-


QJL		fluorocytosine to 5-fluorouracil and inhibited tumor growth in vivo," Proc. Of the Amer. Assoc. for Can. Res. 39:512
	C57	King et al., 2000, "Tumor Therapy using <i>Salmonella</i> ," Emerging Drugs 5:211-219
	C58	Klmpel et al., 1990, "Bacteria-Infected Fibroblasts have Enhanced Susceptibility to the Cytotoxic Action of Tumor Necrosis Factor," J. Immunol. 145:711-717
	C59	Lee et al., 1992, "Identification of a <i>Salmonella typhimurium</i> Invasion Locus by Selection for Hyperinvasive Mutants," Proc. Natl. Acad. Sci. USA 89:1847-1851
	C60	Lee et al., 2000, "Comparative evaluation of the acute toxic effects in monkeys, pigs, and mice of a genetically engineered <i>Salmonella</i> strain (VNP20009) being developed as an anti-tumor agent," Int. J. of Toxicology 19:19-25
	C61	Lemmon et al., 1994, "Anaerobic Bacteria as a Gene Delivery System to Tumors," Proc. Am. Assn. Cancer Res. 35:374 (Abstract 2231)
	C62	Lemmon et al., 1997, "Anaerobic Bacteria as a Gene Delivery System that is Controlled by the Tumor Microenvironment," Gene Therapy 4:791-796
	C63	Levine et al., 1987, "Safety, infectivity, immunogenicity, and in vivo stability of two attenuated auxotrophic mutant strains of <i>Salmonella typhi</i> , 541Ty and 543Ty, as live oral vaccines in humans," J. Clin. Invest. 79(3):888-902
	C64	Levine, 1995, "Recombinant and Live Oral <i>Salmonella typhi</i> Vaccines," NIH Project Number 5 R01 AI29471-06
	C65	Lindgren et al., 1996, "Macrophage killing is an essential virulence mechanism of <i>Salmonella typhimurium</i> ," PNAS 93(9) 4197-4201
	C66	Loppnow et al., 1990, "Cytokine Induction by Lipopolysaccharide (LPS) Corresponds to Lethal Toxicity and is Inhibited by Nontoxic <i>Rhodobacter capsulatus</i> LPS," Infect. Immun. 58:3743-3750
	C67	Low et al., 1999, "VNP20009, a genetically modified <i>Salmonella Typhimurium</i> for treatment of solid tumors," Proc. Amer. Assoc. For Can. Res. 40:87
	C68	Low et al., 1999, "Lipid A mutant <i>Salmonella</i> with suppressed virulence and TNF $\alpha$ induction retain tumor-targeting in vivo," Nature Biotechnology, 17:37-41
	C69	Luo et al., 1999, "Genetically modified <i>Salmonella typhimurium</i> inhibited growth of primary tumors and metastases," Abstract #3146. Proc. Amer. Assoc. For Cancer Res. 40:476
	C70	Lytvyn et al., 1992, "Comparison of the Thymidine Kinase Genes from Three Entomopoxviruses," J. Gen. Virol. 73:3235-3240
	C71	MacEwen et al., "Genetically Modified <i>Salmonella</i> for Canine Cancer: a Phase I Study," Abstract 82
	C72	Macnab, 1992, "Genetics and Biogenesis of Bacterial Flagella," Ann. Rev. Genet. 26:131-158
	C73	Mahan et al., 1993, "Selection of Bacterial Virulence Genes that are Specifically Induced in Host Tissues," Science 259:686-688
	C74	Marr et al., 1997, "Tumor immunotherapy using an adenoviral vector expressing a membrane-bound mutant of murine TNF alpha," Gene Therapy 4(11): Abstract
	C75	McLaughlin et al., 1979, "Synergistic Activity of Components of Mycobacteria and Mutant <i>Salmonella</i> in Causing Regression of Line-10 Tumors in Guinea Pigs," Cancer Res. 39:1766-1771
QJL	C76	Michalek, 1994, "Genetically Engineered Oral Vaccines and Caries Immunity," Abstract,

QJL		NIH Project Number 5 R01 DE09081-05
	C77	Mier et al., 2001, "Phase I trial of a Live, Attenuated <i>Salmonella Typhimurium</i> (VNP20009) Administered by Direct Intra-Tumoral (IT) Injection," Proc Am. Soc. Clin. Oncol. 20:29 Abstract
	C78	Miller, 1995, "Entry into Eukaryotic Cells by <i>Salmonella</i> and <i>Yersinia</i> ," NIH Project Number 5 K04 AI01230-02
	C79	Miller et al., 1992, "An Unusual <i>pagC:TnphoA</i> Mutation Leads to an Invasion- and Virulence-Defective Phenotype in <i>Salmonellae</i> ," Infect. Immun. 60:3763-3770
	C80	Miller et al., 1989, "A Two-Component Regulatory System ( <i>phoP phoQ</i> ) Controls <i>Salmonella typhimurium</i> Virulence," Proc. Natl. Acad. Sci. USA 86:5054-5058
	C81	Minton et al., 1995, "Chemotherapeutic Tumor Targeting Using Clostridial Spores," FEMS Micro. Rev. 17:357-364
	C82	Möse and Möse, 1963, "Oncolysis by Clostridia. I. Activity of <i>Clostridium butyricum</i> (M-55) and Other Nonpathogenic Clostridia Against the Ehrlich Carcinoma," Cancer Res. 24:212-216
	C83	Mullen et al., 1992, "Transfer of the Bacterial Gene for Cytosine Deaminase to Mammalian Cells Confers Lethal Sensitivity to 5-Fluorocytosine: a Negative Selection System," Proc. Natl. Acad. Sci USA 89:33-37
	C84	Nauts et al., 1953, "A Review of the Influence of Bacterial Infection and of Bacterial Products (Coley's Toxins) on Malignant Tumors in Man," Acta Medica Scandinavica 145 (Suppl. 276):1-105
	C85	O'Callaghan et al., 1988, "Characterization of aromatic and purine dependent <i>Salmonella typhimurium</i> : Attenuation, persistence, and ability induce protective immunity in BALB/c mice," Infect. and Immun, 56:419-423
	C86	Paglia et al., "Gene Transfer in Dendritic Cells, Induced by Oral DNA Vaccination With S. <i>Typhimurium</i> , Results in Protective Immunity against a Murine Fibrosarcoma," Blood 92:3172-3176
	C87	Paglia et al., 2000, "In vivo correction of genetic defects of monocyte/macrophages using attenuated <i>Salmonella</i> as oral vectors for targeted gene delivery," Gene Therapy 7:1725-1730
	C88	Pan et al., 1995, "A Recombinant <i>Listeria monocytogenes</i> Vaccine Expressing a Model Tumor Antigen Protects Mice Against Lethal Tumor Cell Challenge and Causes Regression of Established Tumors," Nature Medicine 1:471-477
	C89	Parker et al., 1947, "Effect of <i>Histolyticus</i> Infection and Toxin on Transplantable Mouse Tumors," Proc. Soc. Exp. Biol. Med. 161:461-467
	C90	Pawelek et al., 1995, "Macrophage Characteristics of Metastatic Melanoma", J. Invest. Dermatol. 104:605 (Abstract 304)
	C91	Pawelek et al., 1997, "Tumor-targeted <i>Salmonella</i> as a Novel Anti-cancer Vector," Cancer Res., 57:4537-4544
	C92	Pidherney et al., 1993, "In vitro and in vivo Tumoricidal Properties of a Pathogenic Free-Living Amoeba," Cancer Letters 72:91-98
	C93	Platt et al., 2000, "Anti tumor effects of genetically engineered <i>Salmonella</i> in combination with radiation," Eur. J. Cancer, 36:2397-2402
QJL	C94	Pugsley, 1988, "Protein Secretion Across the Outer Membrane of Gram-Negative Bacteria," In: <u>Protein Transfer and Organelle Biogenesis</u> , D and Robbins (eds.), Academic Press, Inc., Harcourt Brace Jovanovich, Publishers, San Diego, pp. 607-652

QJL	C95	Raue and Cashel, 1975, "Regulation of RNA Synthesis in <i>Escherichia coli</i> ," Biochimica et Biophysica Acta 383:290-304
	C96	Reinhard et al., 1950, "Chemotherapy of Malignant Neoplastic Diseases," JAMA 142:383-390
	C97	Saltzman et al., 1996, "Attenuated <i>Salmonella typhimurium</i> Containing Interleukin-2 Decreases MC-38 Hepatic Metastases: a Novel Anti-Tumor Agent," Cancer Biotherapy and Radiopharmaceuticals 11:145-153
	C98	Saltzman et al., 1997, "Patterns of hepatic and splenic colonization by an attenuated strain of <i>Salmonella typhimurium</i> containing the gene for human interleukin-2: a novel anti-tumor agent," Cancer Biother Radiopharm 12:37-45
	C99	Schafer et al., 1992, "Induction of a Cellular Immune Response to a Foreign Antigen by a Recombinant <i>Listeria monocytogenes</i> Vaccine," J. Immunol. 149:53-59
	C100	Schlechte and Elbe, 1988, "Recombinant Plasmid DNA Variation of <i>Clostridium oncolyticum</i> - Model Experiments of Cancerostatic Gene Transfer," Zbl. Bakt. Hyg. A 268:347-356
	C101	Schlechte et al., 1982, "Chemotherapy for Tumours Using Clostridial Oncolysis, Antibiotics and Cyclophosphamide: Model Trial on the UVT 15264 Tumor," Arch. Geschwulstforsch. 52:41-48
	C102	Shaw et al., 1991, "The Human Dioxin-Inducible NAD(P)H: Quinone Oxidoreductase cDNA-Encoded Protein Expressed in COS-1 Cells is Identical to Diaphorase 4," Eur. J. Biochem. 195:171-176
	C103	Sizemore et al., 1995, "Attenuated <i>Shigella</i> as a DNA Delivery Vehicle for DNA-Mediated Immunization," Science 270:299-302
	C104	Sizemore et al., 1997, "Interaction- of <i>salmonella typhi</i> strains with cultured human monocyte-derived macrophages," Infect. Immunity 65:309-312
	C105	Slauch et al., 1994, "In vivo Expression Technology for Selection of Bacterial Genes Specifically Induced in Host Tissues," Meth. Enzymol. 235:481-492
	C106	Somerville et al., 1996, "A Novel <i>Escherichia coli</i> Lipid A Mutant that Produces an Antiinflammatory Lipopolysaccharide," J. Clin. Invest. 97:359-365
	C107	Somerville et al., 1999, "Escherichia coli msbB Gene as a Virulence Factor and a Therapeutic Target," Infect. And Immunity 67(12): 6583-6590
	C108	Sosnowski et al., 1994, "Complications of Bacillus Calmette-Guerin (BCG) Immunotherapy in Superficial Bladder Cancer," Comp. Ther. 20:695-701
	C109	Sternberg and Maurer, 1991, "Bacteriophage mediated generalized transduction in <i>Escherichia coli</i> and <i>Salmonella typhimurium</i> ," Methods in Enzymology, 204:18-43
	C110	Su et al., 1992, "Extracellular Export of Shiga Toxin B-Subunit/Haemolysin A (C-terminus) Fusion Protein Expressed in <i>Salmonella typhimurium</i> aroA-Mutant and Stimulation of B-Subunit Specific Antibody Responses in Mice," Microbial Pathogenesis 13:465-476
	C111	Sunshine et al., 1997, "Mutation of the <i>htrB</i> Gene in Virulent <i>Salmonella typhimurium</i> Strain by Intergeneric Transduction: Strain Construction and Phenotypic Characterization," J. Bacteriol. 179(17):5521-5533
	C112	Sznol et al., 2000, "Use of preferentially replicating bacteria for treatment of cancer," J. Clinical Invest. 105:1027-1030
QJL	C113	Tacket et al., 2000, "Phase 2 clinical trial of attenuated <i>Salmonella enterica</i> serovar <i>typhi</i> oral live vector vaccine CVD 908-htrA in US volunteers," Infect. Immun. 68(3):1196-1201

QJL	C114	Tacket et al., 1997, "Safety of live oral <i>Salmonella typhi</i> vaccine strains with deletions in <i>htrA</i> and <i>aroC</i> <i>aroD</i> and immune response in humans," <i>Infect. Immun.</i> , 65(2):452-456
	C115	Tacket et al., 1997, "Volunteer studies investigating the safety and efficacy of live oral El Tor <i>Vibrio cholerae</i> O1 vaccine strain CVD 111," <i>Am J Trop Med Hyg.</i> 56(5):533-537
	C116	Tacket et al., 1992, "Comparison of the safety and immunogenicity of <i>aroC aroD</i> and <i>cya crp</i> <i>Salmonella typhi</i> strains in adult volunteers," <i>Infect. Immun.</i> 60:536-541
	C117	Takayma et al., 1989, "Diphosphoryl Lipid A from <i>Rhodopseudomonas sphaeroides</i> ATCC 17023 Blocks Induction of Cachectin in Macrophages by Lipopolysaccharide," <i>Infect. Immun.</i> 57:1336-1338
	C118	Thiele et al., 1963, "Oncolysis by Clostridia. IV. Effect of Nonpathogenic Clostridial Spores in Normal and Pathological Tissues," <i>Cancer Res.</i> 24:234-238
	C119	Thiele et al., 1963, "Oncolysis by Clostridia. III. Effects of Clostridia and Chemotherapeutic Agents on Rodent Tumors," <i>Cancer Res.</i> 24:222-232
	C120	Toso et al., 2002, "Phase 1 Study of the Intravenous Administration of Attenuated <i>Salmonella Typhimurium</i> to Patients with Metastatic Melanoma," <i>J. of Clin. Oncol.</i> 20:142-152
	C121	Tuomanen, 1993, "Subversion of Leukocyte Adhesion Systems by Respiratory Pathogens," <i>Am. Soc. Microbiol.</i> 59:292-296
	C122	Ukishima et al., 2000, "An Oral Cd 40 ligand gene therapy against lymphoma using attenuated <i>Salmonella typhimurium</i> ," <i>Blood</i> 95:1258-1263
	C123	Vaara et al., 1999, "Outer membrane permeability barrier in <i>Escherichia coli</i> mutants that are defective in the late acyltransferases of lipid A biosynthesis," <i>J. Bacteriol.</i> 181(6):1459-1462
	C124	Vinopal, 1987, "Selectable Phenotypes," from <i>Escherichia coli</i> and <i>Salmonella typhimurium</i> , Cellular and Molecular Biology, Neidhardt et al. (ed.), pp. 990-1015
	C125	Wolfe et al., 1971, "Salmonellosis in Patients with Neoplastic Disease," <i>Arch. Intern. Med.</i> 128:547-554
	C126	Zheng et al., 1997, "Attenuated <i>Salmonella typhimurium</i> inhibited tumor metastasis in vivo," <i>Proc Amer Assoc. Can Res.</i> 38:9
QJL	C127	Zheng et al., 2000, "Tumor amplified protein expression therapy: <i>Salmonella</i> as a tumor-selective protein delivery vector," <i>Oncol Res.</i> 12(3):127-35

EXAMINER /Q. Janice Li/ (06/27/2006)	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

1

**Complete If Known**

<b>Application Number</b>	10/738,423
<b>Filing Date</b>	December 16, 2003
<b>First Named Inventor</b>	Ivan C. KING
<b>Art Unit</b>	1632
<b>Examiner Name</b>	R. Shukla
<b>Attorney Docket Number</b>	873-Z-US

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
QJL	1	Curtiss, 2002, "Bacterial infectious disease control by vaccine development," J. Clin. Invest. 110(8):1061-1066	
QJL	2	Dietrich, et al., 1998, "Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attenuated suicide Listeria monocytogenes," Nature Biotechnology 16:181-185	
QJL	3	Dietrich, et al., 2000, "Bacterial Systems for the Delivery of Eukaryotic Antigen Expression Vectors," Antisense & Nucleic Acid Drug Development 10:391-399	
QJL	4	Grillot-Courvalin, et al., 1998, "Functional gene transfer from intracellular bacteria to mammalian cells," Nature Biotechnology 16:862-866	
QJL	5	Pascual, et al., 1997, "Oral Bacterial Vaccine Vectors for the Delivery of Subunit and Nucleic Acid Vaccines to the Organized Lymphoid Tissue of the Intestine," Behring Inst. Mitt. 98:143-152	
QJL	6	Titball and Williamson, 2001, "Vaccination against bubonic and pneumonic plague," Vaccine 19:4175-4184	


Examiner Signature	/Q. Janice Li/ (06/27/2006)	Date Considered	
--------------------	-----------------------------	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
do a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>		Application Number	10/738,423
		Filing Date	December 16, 2003
		First Named Inventor	Ivan C. KING
		Art Unit	1632
		Examiner Name	R. Shukla
		Attorney Docket Number	873-Z-US
Sheet	1	of	1

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1

of

## **FOREIGN PATENT DOCUMENTS**

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> "Kind Code <sup>5</sup> " (if known)				
OJI	1	EP 0338679	10-25-1989	Genentech, Inc.		
OJI	2	WO 97/08955	03-13-1997	Dept. of the Army, U.S. Govt.		

Examiner Signature	/Q. Janice Li/ (06/27/2006)	Date Considered	
--------------------	-----------------------------	-----------------	--

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **Applicant's unique citation designation number (optional).** <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.